-
公开(公告)号：US20110183436A1
公开(公告)日：2011-07-28
申请号：US13024963
申请日：2011-02-10
申请人： George Jackowski , Tracy Van Lieshout , Brad Thatcher , Rulin Zhang , Jason Yantha , Michele Rasamoelisolo
发明人： George Jackowski , Tracy Van Lieshout , Brad Thatcher , Rulin Zhang , Jason Yantha , Michele Rasamoelisolo
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N2800/325
摘要： The invention provides an assay for the quantification of circulating glycophorin in biological fluid samples. The circulating glycophorin measured by this assay is a truncated glycophorin diagnostic for congestive heart failure (CHF).
摘要翻译： 本发明提供了用于定量生物流体样品中循环血型糖蛋白的测定。 通过该测定测量的循环血型糖蛋白是用于充血性心力衰竭（CHF）的截短的血型糖蛋白诊断。
-
公开(公告)号：US08263351B2
公开(公告)日：2012-09-11
申请号：US13024963
申请日：2011-02-10
申请人： George Jackowski , Tracy Van Lieshout , Brad Thatcher , Rulin Zhang , Jason Yantha , Michele Rasamoelisolo
发明人： George Jackowski , Tracy Van Lieshout , Brad Thatcher , Rulin Zhang , Jason Yantha , Michele Rasamoelisolo
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N2800/325
摘要： The invention provides an assay for the quantification of circulating glycophorin in biological fluid samples. The circulating glycophorin measured by this assay is a truncated glycophorin diagnostic for congestive heart failure (CHF).
摘要翻译： 本发明提供了用于定量生物流体样品中循环血型糖蛋白的测定。 通过该测定测量的循环血型糖蛋白是用于充血性心力衰竭（CHF）的截短的血型糖蛋白诊断。
-
公开(公告)号：US20050100964A1
公开(公告)日：2005-05-12
申请号：US10706599
申请日：2003-11-11
申请人： George Jackowski , Tracy Van Lieshout , Brad Thatcher , Rulin Zhang , Jason Yantha , Michele Rasamoelisolo
发明人： George Jackowski , Tracy Van Lieshout , Brad Thatcher , Rulin Zhang , Jason Yantha , Michele Rasamoelisolo
IPC分类号： G01N33/53 , G01N33/543 , G01N33/577 , G01N33/68
CPC分类号： G01N33/6893 , G01N2800/325
摘要： The invention provides an assay for the quantification of circulating glycophorin in biological fluid samples. The circulating glycophorin measured by this assay is a truncated glycophorin diagnostic for congestive heart failure (CHF).
摘要翻译： 本发明提供了用于定量生物流体样品中循环血型糖蛋白的测定。 通过该测定测量的循环血型糖蛋白是用于充血性心力衰竭（CHF）的截短的血型糖蛋白诊断。
-
34.发明授权Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events 有权胆固醇吸收抑制剂和ω-3脂肪酸用于降低胆固醇和预防或减少心血管，心脏和血管事件公开(公告)号：US08952000B2
公开(公告)日：2015-02-10
申请号：US13584403
申请日：2012-08-13
IPC分类号： A61K31/5377 , A61K31/397 , A61K45/06 , A61K31/202 , A61K31/557
CPC分类号： A61K31/397 , A61K31/202 , A61K31/557 , A61K31/66 , A61K45/06 , A61K47/22 , A61K2300/00
摘要： A composition and a method of treatment utilizing a combination of lipid lowering cholesterol absorption inhibitors, e.g. azetidinones, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught. EPA+DHA are about 80% of the total formulation and about 89% of the total omega 3 fatty acid content of the composition. The formulation may further contain specific amounts of arachidonic acid (AA), stearidonic acid (SDA), and alpha-linolenic acid (ALA).
摘要翻译： 使用降血脂胆固醇吸收抑制剂的组合的组合物和治疗方法，例如， 氮杂环丁酮与含有约90％或更多的ω3脂肪酸的ω-3脂肪酸制剂的混合物，其重量包括二十碳五烯酸（EPA），多糖五烯酸（DPA）和二十二碳六烯酸（DHA）的组合，其重量比为 EPA：DHA为5.7至6.3，其中EPA，DHA和DPA的总和占总制剂的约82重量％，并且教导了组合物的总ω3脂肪酸含量的约92％。 EPA + DHA占组合物总配制物的约80％，总ω3脂肪酸含量的约89％。 制剂还可以含有特定量的花生四烯酸（AA），十八碳四烯酸（SDA）和α-亚麻酸（ALA）。
-
35.发明授权Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels 有权欧米加3脂肪酸用作处方医疗食品和欧米加3脂肪酸诊断测定用于心血管疾病（CVD）的心血管疾病患者的膳食管理，血液中EPA和DHA水平不足公开(公告)号：US09119826B2
公开(公告)日：2015-09-01
申请号：US13584428
申请日：2012-08-13
IPC分类号： A61K31/202 , A61K31/685 , A61P9/00 , A61K31/232 , A61K45/06
CPC分类号： A61K31/202 , A61K31/232 , A61K31/66 , A61K45/06 , A61K47/22 , G01N33/92 , G01N2800/32 , A61K2300/00
摘要： The present invention provides a kit for the dietary management of cardiovascular patients with cardiovascular disease who are deficient in blood Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) levels, the kit including a diagnostic assay for determining blood levels of EPA, DHA and Docosapentaenoic acid (DPA) and a pharmaceutical grade prescription medical food omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of EPA, DPA and DHA in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA are about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition. The kit may further contain instructions for use of its components.
摘要翻译： 本发明提供了一种用于膳食管理心血管疾病心血管疾病的试剂盒，其缺乏血液二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）水平，该试剂盒包括用于测定EPA，DHA和Docosapentaenoic 酸（DPA）和药物级处方医用食品ω-3脂肪酸制剂，其含有约90％或更多的ω-3脂肪酸，包括EPA，DPA和DHA的组合，EPA：DHA的重量比为5.7至 6.3，其中EPA，DHA和DPA的总和为总制剂的约82重量％，并且组合物的总ω3脂肪酸含量的约92％。 试剂盒还可以包含使用其组分的说明书。
-
36.发明授权公开(公告)号：US08951514B2
公开(公告)日：2015-02-10
申请号：US13584480
申请日：2012-08-13
IPC分类号： A61K31/202 , A61K31/4155 , A61K31/4412 , A61K35/60 , A61K35/34 , A61K35/44 , A61K31/22 , A61K31/40 , A61K45/06 , A61K47/12 , A61K31/366 , A61K31/404 , A61K31/4418 , A61K31/47 , A61K31/662
CPC分类号： A61K31/202 , A61K9/48 , A61K31/201 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/404 , A61K31/405 , A61K31/44 , A61K31/4418 , A61K31/47 , A61K31/505 , A61K31/557 , A61K31/662 , A61K45/06 , A61K47/12 , A61K47/22 , A61K2300/00
摘要： A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.
摘要翻译： 使用组合的组合物和方法，使用组合的他汀类药物（或HMG-CoA还原酶抑制剂），一类用于通过抑制酶HMG-CoA还原酶来降低胆固醇水平的药物，其中含有ω-3脂肪酸制剂 大约90％或更多的ω3脂肪酸，包括二十碳五烯酸（EPA），多糖五烯酸（DPA）和二十二碳六烯酸（DHA）的组合，EPA：DHA的重量比为5.7至6.3，其中 EPA，DHA和DPA占总制剂的约82重量％，并且教导了组合物的总ω3脂肪酸含量的约92％。
-
37.发明授权Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics 有权用抗肥胖制剂和ω-3脂肪酸治疗心血管疾病患者（CVD）和糖尿病患者体重减轻的方法公开(公告)号：US08715648B2
公开(公告)日：2014-05-06
申请号：US13584443
申请日：2012-08-13
IPC分类号： A61K31/202 , A61K31/4155 , A61K31/4412
CPC分类号： A61K31/202 , A61K31/4155 , A61K31/44 , A61K31/4412 , A61K31/454 , A61K45/06 , A61K2300/00
摘要： Combinations of one or more anti-obesity drugs with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight comprised of a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA comprise about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics.
摘要翻译： 一种或多种抗肥胖药物与包含约90％或更多的ω-3脂肪酸的ω-3脂肪酸制剂的混合物与二十碳五烯酸（EPA），二十碳五烯酸（DPA）和二十二碳六烯酸 （DHA），EPA：DHA的重量比为5.7至6.3，其中EPA，DHA和DPA的总和占总制剂的约82重量％，总ω3脂肪酸含量的约92％ 用于降低心血管疾病患者（CVD）和糖尿病患者体重的组合物。
-
-
-
-
-
-
搜索结果
37 条记录 (耗时 0.022 秒)
